Fortive (FTV) – Investment Analysts’ Recent Ratings Changes

Fortive (NYSE: FTV) has recently received a number of price target changes and ratings updates:

  • 2/12/2018 – Fortive had its price target raised by analysts at JPMorgan Chase & Co. from $82.00 to $84.00. They now have an “overweight” rating on the stock.
  • 2/9/2018 – Fortive had its price target lowered by analysts at BMO Capital Markets from $88.00 to $87.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Fortive had its “hold” rating reaffirmed by analysts at Royal Bank of Canada.
  • 2/9/2018 – Fortive had its price target raised by analysts at Citigroup Inc from $76.00 to $79.00. They now have a “neutral” rating on the stock.
  • 1/29/2018 – Fortive was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fortive Corporation is benefiting from strength in developed markets and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”
  • 1/26/2018 – Fortive had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $88.00 price target on the stock.
  • 1/24/2018 – Fortive was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $83.00 price target on the stock. According to Zacks, “Fortive Corporation is benefiting from strength in developed markets and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”
  • 1/22/2018 – Fortive is now covered by analysts at UBS Group AG. They set a “buy” rating on the stock.
  • 1/17/2018 – Fortive was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $83.00 price target on the stock. According to Zacks, “Fortive Corporation is currently benefiting from strength in developed markets, improved performance by Tektronix and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”
  • 1/16/2018 – Fortive was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fortive Corporation is currently benefiting from strength in developed markets, improved performance by Tektronix and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”
  • 1/11/2018 – Fortive was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $82.00 price target on the stock. According to Zacks, “Fortive Corporation is currently benefiting from strength in developed markets, improved performance by Tektronix and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has outperformed the industry it belongs to.”
  • 1/9/2018 – Fortive was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fortive Corporation is currently benefiting from strength in developed markets, improved performance by Tektronix and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”
  • 1/4/2018 – Fortive had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $79.00 price target on the stock.
  • 1/3/2018 – Fortive was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $81.00 price target on the stock. According to Zacks, “Fortive Corporation is currently benefiting from strength in developed markets, improved performance by Tektronix and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”
  • 1/2/2018 – Fortive was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Fortive Corporation is currently benefiting from strength in developed markets, improved performance by Tektronix and automation businesses in North America. Ongoing margin expansion owing to the Fortive Business System, acquisitions and strong free cash flow generation are the positives. We note that acquisitions of Industrial Scientific and Landauer is anticipated to drive recurring revenues. The company’s subscription-based radiation exposure services are focused in the medical end market. However, end market cyclicality, integration issues and uncertainties in the international markets pose concerns. In the past 12 months, the stock has underperformed the industry it belongs to.”

Shares of Fortive Corp (FTV) opened at $74.30 on Tuesday. Fortive Corp has a fifty-two week low of $56.68 and a fifty-two week high of $76.68. The company has a current ratio of 1.83, a quick ratio of 1.47 and a debt-to-equity ratio of 1.07. The company has a market cap of $25,820.00 and a PE ratio of 25.10.

Fortive (NYSE:FTV) last issued its quarterly earnings data on Thursday, February 8th. The technology company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.04. The firm had revenue of $1.81 billion for the quarter, compared to analyst estimates of $1.77 billion. Fortive had a net margin of 15.69% and a return on equity of 30.54%. The company’s revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.68 EPS. equities analysts forecast that Fortive Corp will post 3.4 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, February 23rd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.38%. The ex-dividend date of this dividend is Thursday, February 22nd. Fortive’s dividend payout ratio (DPR) is presently 9.46%.

Fortive Corporation is a diversified industrial growth company. The Company designs, develops, manufactures and markets professional and engineered products, software and services for a range of end markets. The Company operates through two segments: Professional Instrumentation and Industrial Technologies.

Receive News & Ratings for Fortive Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortive Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply